Ahead of the launch of its first major product, Metabolic Switch, we take a look at Juvenescence.
Over the coming weeks, we will be bringing you extracts of 11 company profiles from our Longevity Supplements Report. Each profile includes an assessment of Pre-Clinical and Clinical Studies, Safety and Risks, Target Market and Success Factors and the target Hallmark(s) of Aging for one of their key products.
We also study each of the companies’ IP, team, UVP, product efficacy, competitive advantage, runway and inflection point, and much more. Here’s the lowdown on Juvenescence.
To view a full size version of Juvenescence’s profile please click here.
All about Juvenescence
Juvenescence was founded with a mission to transform what aging means to the world. As the science around aging was starting to accelerate, Juvenescence saw an opportunity to further that science by encouraging collaboration between leading scientists, physicians and investors to create new therapies and products that they hope will empower people to look after their own health. Juvenescence presents a modality-agnostic portfolio of therapies developed by seasoned drug developers and augmented by machine learning.
Juvenescence plans to transform aging and has organised itself into four major divisions, each of which tackles the topic from a different scientific angle: JuvRx focuses on drug therapies; JuvRegeneration spotlights stem cell regeneration; JuvDataScience applies machine learning and AI; and JuvLife emphasises non-prescription IP protected therapies with clinical proof focused on disease prevention.
Juvenescence was founded by three scientist/investors with long-proven track records in healthcare market: Chairman, Jim Mellon, is a Trustee at the Buck Institute for Research on Aging and author of the book, Juvenescence: Investing in the Age of Longevity (2017); CEO, Dr Greg Bailey, is a serial bio-tech entrepreneur as co-founder or director at Portage Biotech, Biohaven, Medivation, Ascent Healthcare Solutions and VirnetX Inc.; CMO, Dr Dec Doogan, has already had a long and successful career including SVP-WW Drug Development at Pfizer and as CEO of Amarin.
The founders of Juvenescence have created an impressive $26 billion of biopharma shareholder value in the past two decades. As CEO, Dr Greg Bailey has stated: “Juvenescence will be an innovative 21st century biotech company. We will focus on disruptive technologies to prevent or delay age-related disease or to modify aging. We incorporate machine learning, social media and a direct relationship with our patients and consumers to empower and facilitate healthy long life.”
JuvLife is the division of Juvenescence that will focus on creating consumer products that are readily available to manage aging and enhance healthspan. Juvenescence anticipates that JuvLife will quickly become established as the trusted source for high quality, science-based, consumer products. These non-Rx products and functional foods are aimed at supporting individuals as they manage their own health and the onset of age-related conditions. “We are determined to become the trusted source for not only high-quality science-based products but helping everyone better understand aging and how to improve their healthspan and lifespan.”
JuvLife has announced that it will be launching its first major product, branded Metabolic Switch Ketone Ester Fuel, in 2021. Each serving of C6 Ketone Di-Ester naturally raises the level of ketones in the blood to quickly generate a state of ketosis that lasts for several hours. Metabolic Switch was invented by scientists at the Buck Institute for Research on Aging and developed in partnership with the team at Juvenescence. It will be available firstly as a chocolate-flavoured nitro beverage, but additional forms, flavours and variants of the product will also be made available as the product line expands. JuvLife is currently finalising clinical studies and other aspects of commercial scale up for Metabolic Switch, and the company expects GRAS approval of the product in 2021.